In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020
Marie Kempf,1,2 Francis F Arhin,3 Alona Kuraieva,4 Eric Utt5 1Laboratory of Bacteriology, University Hospital Angers, Angers, France; 2INCIT, Inserm, CHU Angers, Univ Angers, Nantes Université, Angers, F-49000, France; 3Pfizer Inc, Kirkland, Quebec, Canada; 4Pfizer Inc, New York, NY, USA; 5Pfizer In...
Main Authors: | Kempf M, Arhin FF, Kuraieva A, Utt E |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-01-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/in-vitro-activity-of-ceftaroline-against-isolates-of-gram-positive-bac-peer-reviewed-fulltext-article-IDR |
Similar Items
-
In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
by: Alona Kuraieva, et al.
Published: (2023-07-01) -
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program
by: Peiyao Jia, et al.
Published: (2022-10-01) -
Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019
by: Marie Kempf, et al.
Published: (2022-12-01) -
In vitro activity of ceftaroline against bacterial isolates causing skin and soft tissue and respiratory tract infections collected in Latin American countries, ATLAS program 2016–2020
by: Naglaa Mohamed, et al.
Published: (2024-03-01) -
Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017–2019
by: Eric Utt, et al.
Published: (2023-06-01)